Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Disparities in Clinical Trial Participation Among Medicare Beneficiaries with Hematologic Malignancies from 2006 to 2019: A SEER-Medicare Analysis

Inna Y Gong, Meredith Rosenthal, Mark Soto, Bahar Rafinejad-Farahani, Joseph M Unger, Carmen E Guerra, Rena M Conti, Danielle Rodin

Blood (2024) 144 (Supplement 1): 5113.

https://doi.org/10.1182/blood-2024-206089

Published: 2024

Journal Articles

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Chathuri Abeyakoon, Sita D. Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Christine I Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Michael Crump, John Kuruvilla

Blood (2024) 144 (Supplement 1): 1695.

https://doi.org/10.1182/blood-2024-201189

Published: 2024

Journal Articles

Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis

Inna Gong, Michael Crump, Anca Prica, Andrew Calzavara, Ning Liu, Danielle Rodin, David Hodgson, Lee Mozessohn, Matthew C. Cheung, John Kuruvilla

Blood (2024) 144 (Supplement 1): 3092.

https://doi.org/10.1182/blood-2024-206056

Published: 2024

Journal Articles

Disparities in Clinical Trial Enrollment for Patients with Hematologic Malignancies - a 15-Year Princess Margaret Cancer Centre Experience

Adam Suleman, Anna Santiago, Tyler Pittman, Gilla Shapiro, Anca Prica, Sita D. Bhella, Heather Cole, Katherine Zeman, Gary Rodin, Susanna Sellmann, Amit Oza, Jennifer Jones, Rena M Conti, Meredith Rosenthal, Danielle Rodin

Blood (2024) 144 (Supplement 1): 401.

https://doi.org/10.1182/blood-2024-194613

Published: 2024

Journal Articles

Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada

Tiana Kordbacheh, Anca Prica, Kelvin KW Chan, Mahmood Aminilari, Zharmaine Ante, Ning Liu, Inna Y Gong, Sita D. Bhella, Michael Crump, Abi Vijenthira, John Kuruvilla, Robert Kridel, Christine I Chen, Vishal Kukreti, Chloe Yang, Nauman Malik, David Hodgson, Danielle Rodin

Blood (2024) 144 (Supplement 1): 2272.

https://doi.org/10.1182/blood-2024-201539

Published: 2024

Journal Articles

Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada

Blood (2024) 144 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2024-209364

Published: 2024

Journal Articles

Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy

Chathuri Abeyakoon, Vanessa Murad, Ho-Young Yhim, Inna Gong, John Kuruvilla, Michael Crump, Anca Prica, Vishal Kukreti, Sita D. Bhella, Christine I Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Ur Metser, Robert Kridel, Abi Vijenthira

Blood (2024) 144 (Supplement 1): 4469.

https://doi.org/10.1182/blood-2024-201150

Published: 2024

Journal Articles

Disparities in Phase II and III Clinical Trial Enrollment for Hematologic Malignancies

Inna Y Gong, Bahar Rafinejad-Farahani, Haris Majeed, Mark Soto, Rena M Conti, Joseph M Unger, Carmen E Guerra, Meredith Rosenthal, Danielle Rodin

Blood (2024) 144 (Supplement 1): 5100.

https://doi.org/10.1182/blood-2024-206450

Published: 2024

Journal Articles

Anthracycline Exposure and Breast Cancer Risk in Female Hodgkin Lymphoma Survivors

Karla Machlab, Vivian Aghanya, Lee Mozessohn, Michael Crump, Danielle Rodin, Ning Liu, Anca Prica

Blood (2024) 144 (Supplement 1): 4432.

https://doi.org/10.1182/blood-2024-204618

Published: 2024

Journal Articles

Routine Pre-Apheresis Markers As Predictors for Efficacy and Safety Outcomes Following CD19 CAR-T Cell Therapy - a Single Center Experience

Blood (2024) 144 (Supplement 1): 6548.

https://doi.org/10.1182/blood-2024-205736

Published: 2024

Journal Articles

Virtual Care Use for Patients with Hematologic Malignancies - a Natural Policy Experiment

Adam Suleman, Amy Zhihui Zhu, Anna Sinaiko, Anca Prica, Danielle Rodin

Blood (2024) 144 (Supplement 1): 3645.

https://doi.org/10.1182/blood-2024-198042

Published: 2024

Journal Articles

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Sita D. Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Michael Crump, John Kuruvilla, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Christine I Chen

Blood (2024) 144 (Supplement 1): 7791.

https://doi.org/10.1182/blood-2024-210635

Published: 2024

Journal Articles

Delays from Progression to Initial Appointment Occur with External Referrals for CAR T-Cell Therapy but Do Not Impact Survival

Sita D. Bhella, Katrina Hueniken, Osamah Jamal S. Jarallah, Melissa Teixeira Maltez, Rachel Aitken, Carmel Waldron, Michael Crump, John Kuruvilla, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Christine I Chen

Blood (2024) 144 (Supplement 1): 7581.

https://doi.org/10.1182/blood-2024-211007

Published: 2024

Journal Articles

A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Tiana Kordbacheh, Anca Prica, Kelvin KW Chan, Mahmood Aminilari, Zharmaine Ante, Ning Liu, Inna Y Gong, Sita Bhella, Michael Crump, Abi Vijenthira, John Kuruvilla, Robert Kridel, Christine I Chen, Vishal Kukreti, Chloe Yang, Nauman Malik, David Hodgson, Danielle Rodin

Blood (2024) 144 (Supplement 1): 5134.

https://doi.org/10.1182/blood-2024-206375

Published: 2024

Journal Articles

Management and Outcomes for Primary Mediastinal B-Cell Lymphoma Patients with Partial Metabolic Response

David Hodgson, Mahmood Aminilari, Donna Liao, Xiang Y Ye, Ur Metser, Michael Crump, John Kuruvilla, Abi Vijenthira, Vishal Kukreti, Robert Kridel, Richard Tsang, Sita D. Bhella, Danielle Rodin, Anca Prica

Blood (2023) 142 (Supplement 1): 988.

https://doi.org/10.1182/blood-2023-190983

Published: 2023

Journal Articles

Clinical Characteristics and Disease Outcomes in Primary Bone Lymphoma: Retrospective Study

Esther Bronwyn Ting, Sahar Khan, Manjula Maganti, Sita Bhella, Michael Crump, David C. Hodgson, Robert Kridel, Vishal Kukreti, John Kuruvilla, Danielle Rodin, Richard Tsang, Anca Prica

Blood (2022) 140 (Supplement 1): 3781–3782.

https://doi.org/10.1182/blood-2022-166118

Published: 2022

Journal Articles

Virtual Care during the COVID-19 Pandemic Among Patients with Hematologic Malignancies - a Princess Margaret Cancer Centre Experience

Adam Suleman, Abi Vijenthira, Tran Trong, Alejandro Berlin, Anca Prica, Danielle Rodin

Blood (2021) 138 (Supplement 1): 838.

https://doi.org/10.1182/blood-2021-149788

Published: 2021

Journal Articles

Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume

Ho-Young Yhim, Yael Eshet, Ur Metser, Katherine Lajkosz, Matthew Cooper, Anca Prica, Vishal Kukreti, Sita Bhella, Noemie Lang, Wei Xu, Danielle Rodin, David Hodgson, Richard Tsang, Michael Crump, John Kuruvilla, Robert Kridel

Blood (2021) 138 (Supplement 1): 1383.

https://doi.org/10.1182/blood-2021-148942

Published: 2021

Journal Articles

The Use of Virtual Care in Patients with Hematologic Malignancies - a Scoping Review

Adam Suleman, Abi Vijenthira, Alejandro Berlin, Anca Prica, Danielle Rodin

Blood (2021) 138 (Supplement 1): 1933.

https://doi.org/10.1182/blood-2021-152021

Published: 2021

Journal Articles

The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of Overall Survival

Lourdes Calvente, MD, Manjula Maganti, MSc, Mary Gospodarowicz, MD FRCPC, David C. Hodgson, MD MPH, FRCPC, Danielle Rodin, MD MPH, FRCPC, Alexander Sun, MD FRCPC, Richard Tsang, MD FRCPC, Robert Kridel, MDMPH,PhD, Vishal Kukreti, MD, Anca Prica, MD, Michael Crump, MD FRCPC, John Kuruvilla, MD

Blood (2019) 134 (Supplement_1): 1559.

https://doi.org/10.1182/blood-2019-130282

Published: 2019

NARROW

Disparities in Clinical Trial Participation Among Medicare Beneficiaries with Hematologic Malignancies from 2006 to 2019: A SEER-Medicare Analysis

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis

Disparities in Clinical Trial Enrollment for Patients with Hematologic Malignancies - a 15-Year Princess Margaret Cancer Centre Experience

Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada

Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada

Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy

Disparities in Phase II and III Clinical Trial Enrollment for Hematologic Malignancies

Anthracycline Exposure and Breast Cancer Risk in Female Hodgkin Lymphoma Survivors

Routine Pre-Apheresis Markers As Predictors for Efficacy and Safety Outcomes Following CD19 CAR-T Cell Therapy - a Single Center Experience

Virtual Care Use for Patients with Hematologic Malignancies - a Natural Policy Experiment

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Delays from Progression to Initial Appointment Occur with External Referrals for CAR T-Cell Therapy but Do Not Impact Survival

A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Management and Outcomes for Primary Mediastinal B-Cell Lymphoma Patients with Partial Metabolic Response

Clinical Characteristics and Disease Outcomes in Primary Bone Lymphoma: Retrospective Study

Virtual Care during the COVID-19 Pandemic Among Patients with Hematologic Malignancies - a Princess Margaret Cancer Centre Experience

Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume

The Use of Virtual Care in Patients with Hematologic Malignancies - a Scoping Review

The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of Overall Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only